lenalidomide has been researched along with enzastaurin in 6 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 188 | 52 | 99 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Hagemeister, FB | 1 |
| Bari, A; Civallero, M; Cosenza, M; Sacchi, S | 1 |
| Bari, A; Civallero, M; Cosenza, M; Grisendi, G; Marcheselli, L; Roat, E; Sacchi, S | 1 |
| Ogura, M | 1 |
| Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
1 review(s) available for lenalidomide and enzastaurin
| Article | Year |
|---|---|
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
1 trial(s) available for lenalidomide and enzastaurin
| Article | Year |
|---|---|
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
4 other study(ies) available for lenalidomide and enzastaurin
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Indoles; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2011 |
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Humans; Indoles; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2012 |
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide | 2015 |